ResMed Inc. (NYSE:RMD) Director Ronald R. Taylor sold 4,429 shares of ResMed stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $136.34, for a total transaction of $603,849.86. Following the sale, the director now owns 19,855 shares in the company, valued at approximately $2,707,030.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
RMD traded down $1.40 during trading on Thursday, reaching $135.16. 3,154 shares of the company’s stock were exchanged, compared to its average volume of 575,130. ResMed Inc. has a fifty-two week low of $90.64 and a fifty-two week high of $137.38. The company has a quick ratio of 1.43, a current ratio of 2.06 and a debt-to-equity ratio of 0.61. The business has a 50 day moving average price of $127.97 and a 200 day moving average price of $112.15. The company has a market capitalization of $19.62 billion, a P/E ratio of 37.17, a PEG ratio of 3.27 and a beta of 0.47.
ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $0.95 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.92 by $0.03. ResMed had a net margin of 15.52% and a return on equity of 26.49%. The firm had revenue of $705.00 million for the quarter, compared to the consensus estimate of $701.56 million. During the same quarter in the previous year, the company earned $0.95 earnings per share. The business’s revenue was up 13.1% compared to the same quarter last year. As a group, research analysts forecast that ResMed Inc. will post 3.92 EPS for the current year.
A number of equities research analysts have weighed in on the stock. ValuEngine upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research note on Wednesday, May 1st. Zacks Investment Research upgraded shares of ResMed from a “hold” rating to a “buy” rating and set a $131.00 price target on the stock in a research note on Monday, July 8th. UBS Group upgraded shares of ResMed from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $122.00 to $140.00 in a research note on Monday, July 29th. Finally, Goldman Sachs Group upgraded shares of ResMed from a “neutral” rating to a “buy” rating in a research note on Monday, July 29th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $121.50.
Several large investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its position in shares of ResMed by 7.0% during the 4th quarter. Geode Capital Management LLC now owns 2,020,799 shares of the medical equipment provider’s stock worth $229,741,000 after purchasing an additional 131,732 shares during the last quarter. IFM Investors Pty Ltd lifted its position in shares of ResMed by 7.1% during the 1st quarter. IFM Investors Pty Ltd now owns 9,217 shares of the medical equipment provider’s stock worth $958,000 after purchasing an additional 609 shares during the last quarter. Financial Gravity Wealth Inc. purchased a new stake in shares of ResMed during the 1st quarter worth $51,000. Conning Inc. lifted its position in shares of ResMed by 18.7% during the 1st quarter. Conning Inc. now owns 2,350 shares of the medical equipment provider’s stock worth $244,000 after purchasing an additional 370 shares during the last quarter. Finally, Eukles Asset Management lifted its position in shares of ResMed by 0.8% during the 1st quarter. Eukles Asset Management now owns 18,177 shares of the medical equipment provider’s stock worth $1,890,000 after purchasing an additional 145 shares during the last quarter. Institutional investors own 65.88% of the company’s stock.
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Further Reading: What is a put option?
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.